Thermi, an Almirall S.A. company, introduces ARVATI, its next-generation 510K FDA-cleared, true temperature-controlled radiofrequency platform with patented technology that powers a range of Thermi’s unique and comprehensive procedures that is now commercially available in the United States.

ARVATI delivers rapid, precise, and consistently controlled output of radiofrequency to tissue, thus inducing positive tissue change by stimulating collagen production to enhance various skin areas, including intimate tissue. The ARVATI platform is built upon increased power as well as optimized two-way real time temperature-controlled algorithms.

The new ARVATI platform includes the well-established treatment applications of ThermiTight, ThermiRase, ThermiSmooth Face and ThermiVa, used by clinicians to address common signs of aging, and/or weight loss, which may include fine lines, post-baby body, loose skin, and intimate tissue laxity.

Read the full press release at